Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Emerging Microbes & Infections

We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2020.1746200